Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10240 Sorrento Valley Road, Suite 300 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.atyrpharma.com |
IR: | See website |
Key People | ||
Sanjay S. Shukla President, Chief Executive Officer, Director | Jill M. Broadfoot Chief Financial Officer | Nancy E. Denyes General Counsel, Corporate Secretary |
Business Overview |
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS). |
Financial Overview |
For the fiscal year ended 31 December 2023, aTyr Pharma Inc revenues decreased 97% to $353K. Net loss increased 11% to $50.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase of 23% to $2M (expense), Stock-based Compensation in R&D increase of 14% to $600K (expense). |
Employees: | 56 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $39.26M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.35M as of Dec 31, 2023 |
EBITDA (TTM): | -$54.33M as of Dec 31, 2023 |
Net annual income (TTM): | -$50.39M as of Dec 31, 2023 |
Free cash flow (TTM): | -$37.44M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 67,750,024 as of Mar 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |